Human glucagon receptor antagonists based on alkylidene hydrazides

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Endocrinology

Background:

• The glucagon receptor plays a critical role in glucose homeostasis.
• Developing selective glucagon receptor antagonists is a key strategy for managing type 2 diabetes.
• Existing therapies require optimization for improved efficacy and safety profiles.

Purpose of the Study:

• To synthesize and optimize a series of alkylidene hydrazide derivatives.
• To evaluate the antagonist activity of these compounds at the human glucagon receptor.
• To assess the pharmacokinetic properties and in vivo efficacy of promising candidates.

Main Methods:

• Chemical synthesis and structural optimization of alkylidene hydrazide derivatives.
• In vitro characterization of competitive antagonism at the human glucagon receptor.
• In vivo pharmacokinetic studies and assessment of blood glucose-lowering effects in fasted rats.

Main Results:

• A series of alkylidene hydrazide derivatives containing an alkoxyaryl moiety were successfully optimized.
• The resulting hydrazide-ethers demonstrated potent and competitive antagonism at the human glucagon receptor.
• Pharmacokinetic studies indicated fast clearance for most tested compounds.
• A representative compound, 4-hydroxy-3-cyanobenzoic acid (4-isopropylbenzyloxy-3,5-dimethoxymethylene)hydrazide, exhibited an IC50 of 20 nM and reduced blood glucose levels in fasted rats.

Conclusions:

• Optimized alkylidene hydrazide derivatives are effective human glucagon receptor antagonists.
• The lead compound shows promise for reducing hyperglycemia in vivo.
• Further development of these compounds could lead to novel anti-diabetic therapeutics.